Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening

AIM: In people with type 2 diabetes (T2D) requiring intensification beyond glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well‐tolerated in the LixiLan‐G trial. This exploratory analysis of LixiLa...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Diabetes Obes Metab
Main Authors: Rosenstock, Julio, Blonde, Lawrence, Aroda, Vanita R., Frias, Juan, Souhami, Elisabeth, Ji, Chen, Niemoeller, Elisabeth, Del Prato, Stefano
Formáid: Artigo
Teanga:Inglês
Foilsithe: Blackwell Publishing Ltd 2021
Ábhair:
Original Articles
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252076/
https://ncbi.nlm.nih.gov/pubmed/33565209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14345
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla